课题基金 / 基金详情

Role and therapeutic potential of the atypical MAP kinase ERK3 in basal-like breast cancer progression

Role and therapeutic potential of the atypical MAP kinase ERK3 in basal-like breast cancer progression
非典型 MAP 激酶 ERK3 在基底样乳腺癌进展中的作用和治疗潜力
批准号：
494886
负责人：
Meloche Sylvain
金额：
$7.29万
依托单位：
Institute for Research in Immunology and Cancer (Montreal, QC)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2023
资助国家：
加拿大
项目状态：
已结题
起止时间：
2023-09-01 至 2024-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=494886&lang=en
关键词：
Basal-Like Breast Cancer Chemoresistance Erk3 Genetically-Engineered Mouse Models Genomics Hypoxia Map Kinases Metastasis Proteomics Signal Transduction

项目摘要

项目成果

Meloche Sylvain的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Breast cancer is a common malignancy that affects 1 in 8 Canadian women in their lifetime. Despite progress in understanding the causes of breast cancer and its classification into defined subtypes, treatment of metastatic breast cancer still represents a
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development and preclinical validation of first-in-class dual inhibitors of the atypical MAP kinases ERK3 and ERK4
Role and therapeutic potential of ERK3/ERK4 MAP kinases in acute kidney injury
Regulation, downstream targets and functional specificity of the MAP kinases ERK1 and ERK2
Targeting the degradation of the cyclin-dependent kinase inhibitor p21 as a novel approach to cancer therapy
海外基金